Keros Therapeutics Inc
NASDAQ:KROS
Keros Therapeutics Inc
NASDAQ:KROS
Price:
10.61
USD
-4.24%
Market Closed
Market Cap:
$209.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Keros Therapeutics Inc
NASDAQ:KROS
|
US |
|
Tongtai Machine & Tool Co Ltd
TWSE:4526
|
TW |
|
H
|
Hutter & Schrantz Stahlbau AG
VSE:HST
|
AT |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
US |
|
IIFL Capital Services Ltd
NSE:IIFLCAPS
|
IN |
|
AMG Advanced Metallurgical Group NV
LSE:0LO9
|
NL |
|
S
|
Suzhou Oriental Semiconductor Co Ltd
SSE:688261
|
CN |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
CN |
Income Statement
Earnings Waterfall
Keros Therapeutics Inc
Keros Therapeutics Inc
Income Statement
Keros Therapeutics Inc
Keros Therapeutics Inc
Currency: USD
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||
| Revenue |
10
N/A
|
8
-25%
|
5
-33%
|
3
-50%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
20
+20 000%
|
20
N/A
|
20
0%
|
20
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+1 410%
|
0
+56%
|
0
+16%
|
1
+138%
|
4
+445%
|
215
+5 948%
|
233
+8%
|
247
+6%
|
244
-1%
|
|
| Operating Income | ||||||||||||||||||||||||||
| Operating Expenses |
(21)
|
(26)
|
(31)
|
(39)
|
(47)
|
(52)
|
(57)
|
(65)
|
(76)
|
(85)
|
(100)
|
(108)
|
(115)
|
(130)
|
(140)
|
(155)
|
(170)
|
(180)
|
(189)
|
(205)
|
(214)
|
(225)
|
(233)
|
(203)
|
(173)
|
|
| Selling, General & Administrative |
(3)
|
(5)
|
(8)
|
(10)
|
(13)
|
(15)
|
(17)
|
(19)
|
(21)
|
(23)
|
(25)
|
(26)
|
(28)
|
(29)
|
(31)
|
(33)
|
(35)
|
(37)
|
(39)
|
(39)
|
(41)
|
(41)
|
(45)
|
(46)
|
(46)
|
|
| Research & Development |
(17)
|
(21)
|
(24)
|
(28)
|
(34)
|
(37)
|
(40)
|
(46)
|
(55)
|
(62)
|
(75)
|
(81)
|
(87)
|
(100)
|
(110)
|
(123)
|
(135)
|
(142)
|
(150)
|
(165)
|
(174)
|
(184)
|
(187)
|
(157)
|
(127)
|
|
| Operating Income |
(11)
N/A
|
(18)
-72%
|
(26)
-45%
|
(36)
-36%
|
(47)
-29%
|
(52)
-11%
|
(57)
-9%
|
(65)
-15%
|
(56)
+13%
|
(65)
-15%
|
(80)
-23%
|
(88)
-10%
|
(115)
-31%
|
(130)
-13%
|
(140)
-8%
|
(155)
-11%
|
(170)
-9%
|
(180)
-6%
|
(189)
-5%
|
(204)
-8%
|
(211)
-3%
|
(10)
+95%
|
0
N/A
|
44
+13 870%
|
71
+62%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
21
|
26
|
32
|
23
|
24
|
26
|
27
|
25
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
|
| Total Other Income |
(2)
|
(3)
|
(3)
|
(2)
|
1
|
3
|
2
|
2
|
(0)
|
(0)
|
3
|
8
|
10
|
13
|
14
|
13
|
2
|
(1)
|
(5)
|
(9)
|
0
|
0
|
0
|
0
|
(1)
|
|
| Pre-Tax Income |
(12)
N/A
|
(21)
-72%
|
(29)
-37%
|
(38)
-29%
|
(46)
-21%
|
(49)
-8%
|
(54)
-10%
|
(62)
-15%
|
(57)
+9%
|
(65)
-15%
|
(77)
-18%
|
(80)
-4%
|
(105)
-31%
|
(116)
-11%
|
(127)
-9%
|
(142)
-13%
|
(153)
-7%
|
(160)
-5%
|
(168)
-5%
|
(182)
-8%
|
(187)
-3%
|
15
N/A
|
27
+85%
|
71
+165%
|
92
+29%
|
|
| Net Income | ||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(2)
|
(2)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(10)
|
(8)
|
(7)
|
(5)
|
|
| Income from Continuing Operations |
(12)
|
(21)
|
(29)
|
(38)
|
(46)
|
(49)
|
(54)
|
(62)
|
(59)
|
(67)
|
(79)
|
(82)
|
(105)
|
(116)
|
(127)
|
(142)
|
(153)
|
(160)
|
(168)
|
(182)
|
(187)
|
4
|
19
|
64
|
87
|
|
| Net Income (Common) |
(12)
N/A
|
(21)
-73%
|
(29)
-36%
|
(37)
-28%
|
(45)
-22%
|
(49)
-7%
|
(53)
-10%
|
(61)
-16%
|
(59)
+4%
|
(67)
-14%
|
(79)
-17%
|
(82)
-4%
|
(105)
-28%
|
(116)
-11%
|
(127)
-9%
|
(142)
-13%
|
(153)
-7%
|
(160)
-5%
|
(168)
-5%
|
(182)
-8%
|
(187)
-3%
|
4
N/A
|
19
+346%
|
64
+243%
|
87
+35%
|
|
| EPS (Diluted) |
-0.64
N/A
|
-1.11
-73%
|
-1.44
-30%
|
-1.83
-27%
|
-2.94
-61%
|
-2.08
+29%
|
-2.28
-10%
|
-2.63
-15%
|
-2.52
+4%
|
-2.79
-11%
|
-3.27
-17%
|
-3.2
+2%
|
-4.15
-30%
|
-4.09
+1%
|
-4.27
-4%
|
-4.8
-12%
|
-5.2
-8%
|
-4.49
+14%
|
-4.65
-4%
|
-4.83
-4%
|
-5
-4%
|
0.1
N/A
|
0.46
+360%
|
1.58
+243%
|
2.3
+46%
|
|
Switch to:
Switch to:
See Also
Discover More
